Rating Change
HC Wainwright & Co. analysts initiated coverage on Avidity Biosciences, Inc. (NASDAQ:RNA) with a Buy rating on August 06, 2026.
new coverageNASDAQ:RNA
HC Wainwright & Co. Initiates Coverage on Avidity Biosciences, Inc. (RNA) with Buy
Rating Change HC Wainwright & Co. analysts initiated coverage on Avidity Biosciences, Inc. (NASDAQ:RNA) with a Buy rating on August 06, 2026.
Market Context
Avidity Biosciences, Inc. operates in the Healthcare sector. The stock currently trades at $12.01 with a market capitalization of $9.4B. The stock has declined 75.7% over the past 52 weeks.
Analyst coverage from HC Wainwright & Co. provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Avidity Biosciences, Inc..
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for Avidity Biosciences, Inc.
Among the 10 most recent ratings: 4 Buy, 6 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Aug 06, 2026 | HC Wainwright & Co. | Buy | N/A |
| Jun 18, 2026 | Cantor Fitzgerald | Overweight | N/A |
| May 15, 2026 | Leerink Partners | Outperform | N/A |
| Mar 11, 2026 | Wells Fargo | Overweight | N/A |
| Nov 11, 2025 | Chardan Capital | Neutral | N/A |
Related Tools: Analyst Ratings Dashboard | View RNA Stock Page
Frequently Asked Questions
What does a Buy rating mean for RNA?
A Buy rating from HC Wainwright & Co. reflects the analyst's outlook on Avidity Biosciences, Inc. (NASDAQ:RNA). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the RNA forecast page.